Hsiang-Yin Hsueh

Dr. Hsiang-Yin Hsueh


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
VGValentina Pita Grisanti
Valentina Pita Grisanti
EVEricka Velez-Bonet
Ericka Velez-Bonet
KCKaylin Chasser
Kaylin Chasser
ZHZachary Hurst
Zachary Hurst
ALAlexus Liette
Alexus Liette
ZCZobeida Cruz-Monserrate
Zobeida Cruz-Monserrate
Obesity is a risk factor for pancreatic ductal adenocarcinoma (PDAC), a deadly disease with limited preventive strategies. Lifestyle interventions to decrease obesity represent a potential approach to prevent obesity-associated PDAC. In this study, we examined whether decreasing obesity through physical activity (PA) and/or dietary changes could decrease inflammation in humans and prevent obesity-associated PDAC in mice. Comparison of circulating inflammatory-associated cytokines in subjects (overweight and obese) before and after a PA intervention revealed PA lowered systemic inflammatory cytokines. Mice with pancreatic-specific inducible KrasG12D expression were exposed to PA and/or dietary interventions during and after obesity-associated cancer initiation. In mice with concurrent diet-induced obesity and KrasG12D expression, the PA intervention led to lower weight gain, suppressed systemic inflammation, delayed tumor progression, and decreased proinflammatory signals in the adipose tissue. However, these benefits were not as evident when obesity preceded pancreatic KrasG12D expression. Combining PA with diet-induced weight loss (DI-WL) delayed obesity-associated PDAC progression in the genetically engineered mouse model, but neither PA alone nor combined with DI-WL or chemotherapy prevented PDAC tumor growth in orthotopic PDAC models regardless of obesity status. PA led to the upregulation of Il15ra in adipose tissue. Adipose-specific overexpression of Il15 slowed PDAC growth but only in nonobese mice. Overall, our study suggests that PA alone or combined with DI-WL can reduce inflammation and delay obesity-associated PDAC development or progression. Lifestyle interventions that prevent or manage obesity or therapies that target weight loss–related molecular pathways could prevent progression of PDAC. Significance: Physical activity reduces inflammation and induces changes to adipose-related signaling to suppress pancreatic cancer, supporting the potential of obesity management strategies to reduce the risk of developing pancreatic cancer. See related commentary by Sogunro and Muzumdar, p. 2935

26 October 2021 in Pancreatology
Verified
Journal Article
Closed access
HHHsiang-Yin Hsueh
Hsiang-Yin Hsueh
VGValentina Pita Grisanti
Valentina Pita Grisanti
KGKristyn Gumpper-Fedus
Kristyn Gumpper-Fedus
ALAli Lahooti
Ali Lahooti
MCMyrriah Chavez-Tomar
Myrriah Chavez-Tomar
ZCZobeida Cruz-Monserrate
Zobeida Cruz-Monserrate

Verified
Journal Article
Open access
PDF file
HHHsiang-Yin Hsueh
Hsiang-Yin Hsueh
KGKristyn Gumpper-Fedus
Kristyn Gumpper-Fedus
JPJelmer Poelstra
Jelmer Poelstra
KPKenneth L. Pitter
Kenneth L. Pitter
ZCZobeida Cruz-Monserrate
Zobeida Cruz-Monserrate
Ras signaling regulates many cellular processes in cancer development. While well-known Ras-related oncogenes, such as KRAS, have been extensively explored, the role of other Ras-related genes in cancer remains poorly studied. Dexamethasone-induced Ras-related protein 1 (RASD1), a member of the Ras superfamily, is widely expressed across various tissues and is involved in inhibiting cell growth and inducing apoptosis, suggesting a potential role as a tumor suppressor. Here, we investigated RASD1 expression across multiple tissues and cancers, utilizing data from The Cancer Genome Atlas (TCGA), Human Protein Atlas, and Genotype-Tissue Expression (GTEx) databases. Our analysis revealed a significant downregulation of RASD1 mRNA expression in several cancer types compared to normal tissues, correlating with low levels of promoter methylation. Interestingly, high RASD1 expression correlated with a favorable prognosis in multiple cancers. Immune cell infiltration analysis indicated that elevated RASD1 expression is associated with an increased infiltration of CD4+ T cells and myeloid-derived dendritic cells in cancer. Furthermore, the expression of genes exhibiting similar expression patterns as RASD1 suggest that RASD1 may play a role in interleukin-4-mediated apoptosis and could regulate the transcription of the phosphatase and tensin homolog (PTEN) gene. Overall, these findings suggest that RASD1 may modulate immune signaling and tumor suppressive pathways.

26 June 2026 in Cancer Research
Verified
Journal Article
Closed access
EVEricka Vélez-Bonet
Ericka Vélez-Bonet
KGKristyn Gumpper-Fedus
Kristyn Gumpper-Fedus
KCKaylin M. Chasser
Kaylin M. Chasser
ZHZachary A. Hurst
Zachary A. Hurst
ATAdaliz Torres-Rosado
Adaliz Torres-Rosado
ZCZobeida Cruz-Monserrate
Zobeida Cruz-Monserrate
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor outcomes. Obesity increases the risk of PDAC through metabolic dysregulation and inflammation. Ketogenic diet (KD) can alter metabolism and has been evaluated for its effects on tumor progression in nonobese PDAC using genetically engineered mouse models (GEMM). We hypothesized that KD may also prevent obesity-associated PDAC progression by altering body composition and cancer metabolism. Therefore, male PDAC GEMMs were subjected to diet-induced obesity (DIO) using high-fat diets or maintained on a low-fat diet (LFD) for 15 weeks. Mice were then randomized to continue the initial diets or switch to a KD or matched control diet for 6 weeks. Body weight and composition, glucose tolerance, ketone levels, pancreas histology, and tissue metabolomics were assessed. Furthermore, murine pancreas-derived organoids from DIO or LFD-fed GEMMs were treated with a ketone body and analyzed using untargeted metabolomics. In obese PDAC GEMMs, KD delayed cancer progression independent of weight loss, an effect not observed in nonobese LFD-fed mice. KD-mediated PDAC suppression was associated with enrichment of pancreatic metabolic pathways that support nonglucose energy production. Ketone-treated organoids recapitulated a subset of the KD-associated metabolic differences observed in vivo, suggesting a direct metabolic effect on cancer cells. These findings suggest potential benefits of a KD in preventing obesity-associated PDAC. The diet–cancer metabolic interactions highlight potential opportunities for dietary or metabolic interventions to prevent PDAC in high-risk obese populations. Significance: Ketogenic diet prevents pancreatic cancer progression in obese, but not in nonobese, genetically engineered mouse models and modifies pancreatic metabolic pathways, informing future dietary and therapeutic strategies for high-risk obese populations.

17 June 2026
Verified
Other
Open access
VGValentina Pita Grisanti
Valentina Pita Grisanti
EVEricka Velez-Bonet
Ericka Velez-Bonet
KCKaylin Chasser
Kaylin Chasser
ZHZachary Hurst
Zachary Hurst
ALAlexus Liette
Alexus Liette
ZCZobeida Cruz-Monserrate
Zobeida Cruz-Monserrate
Supplementary Materials and Methods - Clean